Karuna Therapeutics, Inc.

Embera Neurotherapeutics, Inc.

Synagile Corporation

Bruce Rehlaender

Aimesther Betancourt

Roch Thibert

Adam Heller

Ephraim Heller

John C Spiridigliozzi

Julie A Straub

Winston A Vadino

Muralikrishna Duvvuri

Jay Breaux

Kripanath Borah

Parag M Ved

Carol Gloff

John Spiridiglozzi

Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.

Compositions and methods for treating disorders ameliorated by muscarinic receptor activation

Provided are pharmaceutical compositions useful for the treatment and/or prevention of a disorder, such as addiction. For example, pharmaceutical compositions are provided that comprise a first active pharmaceutical component (e.g., metyrapone) and a second active pharmaceutical component (e.g., oxazepam). The compositions may be constructed in such a manner as to limit the physical contact between the first and second active pharmaceutical components, thus preventing any degradation of the active pharmaceutical components resulting form interaction between the two components. The compositions may include at least one pharmaceutically acceptable excipient. Also provided are methods of making the compositions as well as kits containing materials to provide the compositions.

Pharmaceutical compositions and uses thereof

Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof, and a plurality of trospium beads having a core comprising a salt of trospium.

Compositions and methods for treatment of disorders ameliorated by muscarinic receptor activation

Growing community of inventors

Lake Oswego, OR, United States of America

Bruce Rehlaender